Determining preclinical safety of Aclarubicin in pediatric malignancies
Darleen S. Tu, Aaron K Olson, Kimberly S. Waggie, Nicolas M. Garcia, Virginia J. Hoglund, Stephanie I. Walter, Jenna R. Rosinski, Harini Sadeeshkumar, Radhika A. Patel, Erolcan Sayar, Michael C. Haffner, Lisa Maves, Jacques Neefjes, Jay F. Sarthy, Elizabeth R. Lawlor, Shireen S. Ganapathi
This study evaluates Aclarubicin's safety and efficacy in pediatric cancer models, finding it effective with reduced genotoxicity and cardiotoxicity compared to doxorubicin.
Pediatric Blood & Cancer · Nov 26, 2025Peer-reviewedCancer Biology